Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 11, 2011, Pages 2605-2614

  Neukam, Karin ^a   Mira, José A ^a   Ruiz Morales, Josefa ^b   Rivero, Antonio ^c   Collado, Antonio ^d   Torres Cornejo, Almudena ^e,f   Merino, Dolores ^g   de los Santos Gil, Ignacio ^h   Macías, Juan ^a   González Serrano, Mercedes ^b   Camacho, Angela ^c   Parra Garcí, Ginés ^d   Pineda, Juan A ^a   Rivero Juárez, Antonio ^c   Pérez Camacho, Inés ^c   Torre Cisneros, Julián ^c   Aliaga Jiménez, Angelina ^d   López Cortés, Luis ^e   Palacios Muñoz, Rosario ^b   Santos González, Jesús ^b   Márquez Solero, Manuel ^b   Nuño Alvarez, Enrique ^b   Fernández, Andrea ^g   more..

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^d HOSPITAL TORRECÁRDENAS   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f Instituto de Biomedicina de Sevilla   (Spain)

^g HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^h HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Bilirubin elevations; Cirrhosis; Hepatotoxicity; Significant fibrosis; Transaminase elevations

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR PLUS RITONAVIR; BILIRUBIN; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; FOSAMPRENAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR; RITONAVIR PLUS SAQUINAVIR;

ADULT; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; SIDE EFFECT;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RITONAVIR; TRANSAMINASES;

EID: 80054688849     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr357     Document Type: Article

References (31)

1. Pineda JA, García-García JA, Aguilar-Guisado M et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007; 46: 622-30.
2. Brau N, Salvatore M, Ríos-Bedoya CF et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 47-55.
3. Jain MK. Drug-induced liver injury associated with HIV medications. Clin Liver Dis 2007; 11: 615-39.
4. Mira JA, Macías J, Girón-González JA et al. Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother [2006;] 58: 140-6.
5. Rivero A, Mira JA, Pineda JA. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2007; 59: 342-6.
6. Sulkowski MS, Thomas DL, Mehta SH et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 1: 182-9.
7. van Leth F, Phanuphak P, Ruxrungthan K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN study. Lancet 2004; 363: 1253-63.
8. Rachlis A, Clotet B, Baxter J et al. Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3. HIV Clin Trials [2007;] 8: 213-20.
9. Norris D, Patel L, Rizzardini G et al. Efficacy and safety of fosamprenavir/ ritonavir (FPV/r) bid or lopinavir/ritonavir (LPV/r) bid in antiretroviral treatment-naïve subjects co-infected with hepatitis B (HBV) or C (HCV) and HIV (the KLEAN study). In: Abstracts of the Fourth International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, 2007. Abstract MOPEB059. International AIDS Society, Geneva, Switzerland.
10. Absalon J, Thal G, Thiry A et al. Atazanavir is safe and efficacious in HBV and HCV co-infected patients: results of A1424138 (CASTLE). In: Abstracts of the Ninth international Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, 2008. Abstract P136. International AIDS Society, Geneva, Switzerland.
11. Ortiz R, Fourie J, Andrade-Villanueva J et al. Tolerability of once-daily darunavir/r versus lopinavir/r in treatment naïve patients coinfected with hepatitis B and/or C in the ARTEMIS trial. In: Abstracts of the HEP DART: Frontiers in Drug Development for Viral Hepatitis, Hawaii, USA, 2007. Abstract 94. Emory University School of Medicine, Atlanta, GA, USA.
12. Martín-Carbonero L, Nuñez M, González-Lahoz J et al. Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. HIV Clin Trials 2003; 4: 115-278.
13. Palacios R, Vergara S, Rivero A et al. Low incidence of severe liver events in HIV patients with and without hepatitis C or B coinfection receiving lopinavir/ritonavir. HIV Clin Trials 2006; 6: 319-23.
14. Pineda JA, Santos J, Rivero A et al. Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis. J Antimicrob Chemother 2008; 61: 925-32.
15. Merchante N, López-Cortés LF, Delgado-Fernández M et al. Low incidence of severe hepatic toxicity with 1400/100 mg QD fosamprenavir/ritonavir in HIV/HCV-coinfected patients. The TEL-C study. AIDS Patients Care STDS 2011; 7: 395-402.
16. Neukam K, Torres-Cornejo A, Rivero A et al. Hepatic safety of antiretroviral treatment that includes 600/100 mg ritonavir-boosted darunavir twice daily in HIV-infected patients with viral hepatitis. In: Abstracts of the Twelfth Congress of the Andalusian Society of Infectious Diseases, Cadiz, Spain, 2010. Abstract 49.
17. Aranzabal L, Casado JL, Moya J et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005; 40: 588-93.
18. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. January [10,] 2011; 1-166. http://www.aidsinfo.nih.gov/ContentFiles/Adultand AdolescentGL.pdf (10 March 2011, date last accessed).
19. Clumeck N, Pozniak A, Raffi F; EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008; 9: 65-71.
20. Recommendations of Gesida/PNS/AEEH for the management and treatment of the adult patient co-infected with HIV and hepatitis A, B and C virus. Panel de expertos de Gesida, Secretaría del Plan Nacional sobre el Sida (SPNS) y Asociación Española para el Estudio del Hígado (AEEH). Enferm Infecc Microbiol Clin 2010; 28: 31.e1-31.
21. Vergara S, Macías J, Rivero A et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2007; 45: 969-74.
22. Macías J, Girón-González JA, González-Serrano M et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut 2006; 55: 409-14.
23. Martinez E, Arnaiz JA, Podzamzer D et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003; 349: 1036-46.
24. Manfredi R, Calza L, Chiodo F. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. J Acquir Immune Defic Syndr 2004; 35: 492-502.
25. Macias J, Mallolas J, López-Cortes L et al. Liver safety of regimens including two nucleoside analogs plus efavirenz (EFV), nevirapine (NVP) or one ritonavir-boosted protease inhibitor (PI/r) in HIV-infected drug-naïve patients with chronic hepatitis C. In: Abstracts of the Tenth International Congress on HIV and Drug Therapy in HIV Infection, Glasgow, Scotland, 2010. Poster P091. International AIDS Society, Geneva, Switzerland.
26. Gisolf EH, Dreezen C, Danner SA et al. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Clin Infect Dis 2000; 5: 1234-9.
27. Torti C, Lapadula G, Antinori A et al. Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MATER Cohorts. Infection 2009; 37: 224-49.
28. Martin-Carbonero L, Benhamou Y, Puoti M et al. Incidence and predictors of severe liver fibrosis in HIV infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 2004; 38: 128-33.
29. Barreiro P, Rodríguez-Novoa S, Labarga P et al. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J Infect Dis 2007; 195: 973-9.
30. FDA. Highlights of Prescribing Information for Sustivaw (Efavirenz). Amendment 03/2009. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020972s033,021360s021lbl.pdf (10 March 2011, date last accessed).
31. Dieleman JP, Jambroes M, Gyssens IC et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort. AIDS 2002; 16: 737-45.